| Paris | |
| 70 | |
| TxCell is developing innovative, personalized cell immunotherapies using regulatory T-cells (Treg) for severe chronic inflammatory and autoimmune diseases. | |
| Ovasave® is TxCell lead product candidate derived from TxCell's proprietary platform ASTrIA. Ovasave® is a personalized T cell immunotherapy product, based on the properties of autologous ovalbumin-specific regulatory T lymphocytes. A phase IIb placebo controlled study has been initiated in refractory Crohn's Disease patients. This follows a phase I/IIa study in the same patient population, which has been successfully completed and reported positive clinical efficacy and good tolerability. | |
| BOISSEL Stéphane | |
| www.txcell.com | |
| TXCL:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 5 fois.